<?xml version='1.0' encoding='utf-8'?>
<document id="25320939"><sentence text="[Drug-drug interaction with telaprevir or boceprevir in liver transplant patients: about four cases]."><entity charOffset="28-38" id="DDI-PubMed.25320939.s1.e0" text="telaprevir" /><entity charOffset="42-52" id="DDI-PubMed.25320939.s1.e1" text="boceprevir" /><pair ddi="false" e1="DDI-PubMed.25320939.s1.e0" e2="DDI-PubMed.25320939.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25320939.s1.e0" e2="DDI-PubMed.25320939.s1.e1" /></sentence><sentence text="Boceprevir and telaprevir are both direct-acting antivirals indicated, as part of combination therapy for the management of chronic hepatitis C virus (HCV) genotype 1 infection"><entity charOffset="0-10" id="DDI-PubMed.25320939.s2.e0" text="Boceprevir" /><entity charOffset="15-25" id="DDI-PubMed.25320939.s2.e1" text="telaprevir" /><pair ddi="false" e1="DDI-PubMed.25320939.s2.e0" e2="DDI-PubMed.25320939.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25320939.s2.e0" e2="DDI-PubMed.25320939.s2.e1" /></sentence><sentence text=" Transplanted patients treated with anticalcineurines (tacrolimus and cyclosporine) are confronted with major risks of interactions"><entity charOffset="36-53" id="DDI-PubMed.25320939.s3.e0" text="anticalcineurines" /><entity charOffset="55-65" id="DDI-PubMed.25320939.s3.e1" text="tacrolimus" /><entity charOffset="70-82" id="DDI-PubMed.25320939.s3.e2" text="cyclosporine" /><pair ddi="false" e1="DDI-PubMed.25320939.s3.e0" e2="DDI-PubMed.25320939.s3.e0" /><pair ddi="false" e1="DDI-PubMed.25320939.s3.e0" e2="DDI-PubMed.25320939.s3.e1" /><pair ddi="false" e1="DDI-PubMed.25320939.s3.e0" e2="DDI-PubMed.25320939.s3.e2" /><pair ddi="false" e1="DDI-PubMed.25320939.s3.e1" e2="DDI-PubMed.25320939.s3.e1" /><pair ddi="false" e1="DDI-PubMed.25320939.s3.e1" e2="DDI-PubMed.25320939.s3.e2" /></sentence><sentence text=" Indeed, these antiviral are strong inhibitors of the enzyme cytochrome 3A4/A5, responsible for the metabolisme of ciclosprine and tacrolimus"><entity charOffset="115-126" id="DDI-PubMed.25320939.s4.e0" text="ciclosprine" /><entity charOffset="131-141" id="DDI-PubMed.25320939.s4.e1" text="tacrolimus" /><pair ddi="false" e1="DDI-PubMed.25320939.s4.e0" e2="DDI-PubMed.25320939.s4.e0" /><pair ddi="false" e1="DDI-PubMed.25320939.s4.e0" e2="DDI-PubMed.25320939.s4.e1" /></sentence><sentence text=" The literature gives evidence of the dangerousness of this drug-drug interaction" /><sentence text=" We report four clinical cases illustrating the dosage adaptations at liver transplant patients and treated by telaprevir or boceprevir"><entity charOffset="111-121" id="DDI-PubMed.25320939.s6.e0" text="telaprevir" /><entity charOffset="125-135" id="DDI-PubMed.25320939.s6.e1" text="boceprevir" /><pair ddi="false" e1="DDI-PubMed.25320939.s6.e0" e2="DDI-PubMed.25320939.s6.e0" /><pair ddi="false" e1="DDI-PubMed.25320939.s6.e0" e2="DDI-PubMed.25320939.s6.e1" /></sentence><sentence text=" To protect the immunosuppressive efficiency, a multidisciplinary care and narrow monitoring of the interaction between immunosuppressing agents and protease inhibitors were necessary" /><sentence text=" " /></document>